Pharma Leaders to Meet Trump in Push to Tweak Drug Policies
The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...
‘Very concerning’: What NIH cuts would mean for D.C.-area biotech companies, universities
The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
Business Integration and Pharma Segments Are Key Swing Factors for Kirin's Fiscal 2025 Earnings
However, the shift of strategic direction to wellness has raised uncertainty over Kirin’s long-term growth prospects, where execution plays a key role in integrating the acquired subsidiary and ...
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...
manilatimes16h
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...
Alvotech and Teva’s BLA filing for AVT06 accepted by FDA
Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...
Pharmaceutical Technology17h
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...